L3VLUP
ProSign in

CRL · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

CRLLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • CRL
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterCRLLLY
Q3 202012 holders, $1.4bn33 holders, $14.1bn
Q4 202015 holders, $1.5bn29 holders, $17.3bn
Q1 202114 holders, $2.1bn24 holders, $23.0bn
Q2 202114 holders, $2.5bn24 holders, $27.8bn
Q3 202111 holders, $2.8bn31 holders, $29.9bn
Q4 202115 holders, $2.7bn31 holders, $34.7bn
Q1 202215 holders, $1.8bn24 holders, $35.3bn
Q2 202217 holders, $1.1bn33 holders, $42.7bn
Q3 202216 holders, $1.1bn31 holders, $43.4bn
Q4 202211 holders, $1.1bn31 holders, $46.6bn
Q1 20239 holders, $864m33 holders, $44.3bn
Q2 20239 holders, $755m37 holders, $59.6bn
Q3 202310 holders, $475m44 holders, $67.6bn
Q4 20239 holders, $536m45 holders, $73.6bn
Q1 20249 holders, $664m41 holders, $95.3bn
Q2 20247 holders, $385m43 holders, $110bn
Q3 20249 holders, $898m45 holders, $107bn
Q4 202410 holders, $1.0bn46 holders, $93.9bn
Q1 202512 holders, $1.0bn42 holders, $98.4bn
Q2 202515 holders, $1.3bn43 holders, $93.2bn
Q3 202511 holders, $1.2bn39 holders, $86.7bn
Q4 202516 holders, $2.1bn41 holders, $123bn
Q1 202614 holders, $2.7bn39 holders, $106bn
Q2 202612 holders, $3.7bn44 holders, $132bn
CRL

Charles Riv Labs Intl Inc

Holders
12
Reported value
$1.0bn
Buyers
9
Sellers
4

Breadth +5 among 95 comparable managers.

Health care services and researchHealthcare: biopharma and medtech · L3VLUP
LLY

Eli Lilly & Co

Holders
42
Reported value
$98.4bn
Buyers
22
Sellers
22

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2025

Among the 47 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only CRL (5)

Baillie Gifford & Co, D1 Capital Partners LP, Moore Capital Management LP, Two Sigma Investments LP, Voloridge Investment Management LLC

Only LLY (35)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, Egerton Capital UK LLP, Eisler Capital Management Ltd, Element Capital Management LLC, Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Lone Pine Capital LLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, and 10 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →